Predicting IDH mutation status in grade II gliomas using amide proton transfer‐weighted (APTw) MRI
Magnetic Resonance in Medicine2017Vol. 78(3), pp. 1100–1109
Citations Over TimeTop 1% of 2017 papers
Shanshan Jiang, Tianyu Zou, Charles G. Eberhart, Maria A.V. Villalobos, Hye‐Young Heo, Yi Zhang, Yu Wang, Xianlong Wang, Hao Yu, Yongxing Du, Peter C.M. van Zijl, Zhibo Wen, Jinyuan Zhou
Abstract
IDH-wildtype lesions typically were associated with relatively high APTw signal intensities as compared with IDH-mutant lesions. The APTw signal could be a valuable imaging biomarker by which to identify IDH1 mutation status in grade II gliomas. Magn Reson Med 78:1100-1109, 2017. © 2017 International Society for Magnetic Resonance in Medicine.
Related Papers
- → Isocitrate dehydrogenase mutations in gliomas(2011)86 cited
- → Isocitrate dehydrogenase 1: what it means to the neurosurgeon(2013)22 cited
- → Inhibition of mutant IDH1 in acute myeloid leukaemia(2014)9 cited
- → New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status(2011)7 cited
- Isocitrate dehydrogenase 1 mutations and human gliomas(2011)